US11407795B2ActiveUtilityA1
Peptides and methods for the treatment of diabetes
Est. expiryMar 9, 2037(~10.7 yrs left)· nominal 20-yr term from priority
C07K 14/62A61K 2039/577A61P 3/10C07K 7/08C12N 9/0004C07K 14/435A61K 38/00A61K 39/0008C12N 2501/998C12N 2501/2302A61K 35/17C12N 5/0636
94
PatentIndex Score
4
Cited by
39
References
5
Claims
Abstract
The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG [SEQ ID NO: 26] and their use in the treatment of type 1 diabetes and the generation of cytolytic CD4+ T cell.
Claims
exact text as granted — not AI-modifiedThe invention claimed is:
1. A method of treating type 1 diabetes comprising administering to a subject in need thereof a therapeutically sufficient amount of an immunogenic peptide comprising the amino acid sequence of HCXX[CST]SLQPLALEGSLQK [SEQ ID NO:7] or H[CST]XXCSLQPLALEGSLQK [SEQ ID NO:8] wherein X stands for any amino acid, and wherein the peptide has a length of between 12 and 50 amino acids.
2. The method of claim 1 , wherein the amino acid sequence comprises HCXXCSLQPLALEGSLQK [SEQ ID NO: 9] wherein X stands for any amino acid.
3. The method of claim 1 , wherein the amino acid sequence consists of HCPYCSLQPLALEGSLQKRG [SEQ ID NO: 26].
4. The method of claim 1 , wherein the amino acid sequence consists of HCXX[CST]SLQPLALEGSLQK [SEQ ID NO:7] or H[CST]XXCSLQPLALEGSLQK [SEQ ID NO:8] wherein X stands for any amino acid.
5. The method of claim 1 , wherein the amino acid sequence consists of HCXXCSLQPLALEGSLQK [SEQ ID NO: 9] wherein X stands for any amino acid.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.